Literature DB >> 33758596

Updated applications of Ultrasound in Uterine Cervical Cancer.

Yi-Hsuan Hsiao1,2,3,4,5, Shun-Fa Yang1,2,6, Ya-Hui Chen4, Tze-Ho Chen3,4, Horng-Der Tsai3,4, Ming-Chih Chou1,2, Pang-Hsin Chou3,4.   

Abstract

Cervical cancer is a common gynecologic malignancy worldwide. It is the fourth for both incidence and mortality. For cervical cancer, imaging and pathology assessments are incorporated in the revised 2018 Federation of Gynecology and Obstetrics (FIGO) staging system. Uses of imaging techniques for the pre-treatment work-up of cervical cancer have been increasing. Among imaging techniques for the evaluation of cervical cancer, ultrasound is cheaper, faster and widely available than other imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI). Advanced technique in ultrasound, such as three-dimension (3D) ultrasound and color Doppler, have improved the clinical application of ultrasound in cervical cancer. Ultrasound may provide highly accurate information on detecting tumor presence and evaluating local tumor extent if performed by ultrasound-trained gynecologists; the experience of readers is also critical for correct pretreatment staging and assessment of response to treatment. Sonographic images could be useful to predict response of neoadjuvant chemotherapy, radiotherapy, chemotherapy and concurrent chemoradiotherapy in patients with cervical cancer. This review article attempted to present the most updated specific applications of ultrasound in cervical cancer. © The author(s).

Entities:  

Keywords:  cervical cancer; staging; therapy; ultrasound

Year:  2021        PMID: 33758596      PMCID: PMC7974902          DOI: 10.7150/jca.49479

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  1 in total

1.  Utility of 3T MRI in Women with IB1 Cervical Cancer in Determining the Necessity of Less Invasive Surgery.

Authors:  Soo Young Jeong; Byung Kwan Park; Chel Hun Choi; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Byoungi-Gie Kim
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.